Mary McCoy
Lancaster, CANPI 1306841069
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 99 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 18 manufacturers reported payments, led by GSK at 25.0% of the total. Reporting peaked in 2019 at $1,053 and has fallen 95.4% since, to $48 in 2022.
Across 99 payments — averaging $13.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$331
- Boehringer Ingelheim$265
- Novartis$140
- Advanced Respiratory, Inc$112
- Merck$109
- Pfizer$89
- plus $280 from 12 others
What the payments were for
- Food & beverage$1,325100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 23 | $331 |
| Boehringer Ingelheim | 33 | $265 |
| Novartis | 8 | $140 |
| Advanced Respiratory, Inc | 6 | $112 |
| Merck | 7 | $109 |
| Pfizer | 6 | $89 |
| Johnson & Johnson | 2 | $37 |
| Astellas Pharma US Inc | 2 | $36 |
| Lilly USA, LLC | 2 | $27 |
| Radius Health, Inc. | 1 | $26 |
| Boston Scientific | 1 | $26 |
| Amgen | 1 | $26 |
| AstraZeneca | 2 | $24 |
| Sanofi-aventis U.S. LLC | 1 | $19 |
| AbbVie | 1 | $19 |
| Novo Nordisk | 1 | $16 |
| Avanir Pharmaceuticals, Inc. | 1 | $12 |
| Circassia Inc. | 1 | $11 |
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.